The investigators reported a significantly greater prevalence of ED in men with BPH (P < .0001).

“Allowing these women to have a fulfilling life after cancer is one of the best things we can do as physicians,” says Talia A. Helman, MD.

For the survey question “Do 5-ARIs reduce serum PSA?” 8 (9.4%) respondents said “no” and 25 (29.4%) said “not sure.”

Data from a Mayo Clinic study show, despite some reports of discomfort and dissatisfaction, a majority of patients receiving penile prosthesis are satisfied 1 year in.

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

Data from a new SMSNA 2024 abstract show an association between significantly high BMI and risk of azoospermia and oligospermia.

Following use of MED3000, the investigators reported significant improvements in all 5 SEP questions in both patients and partners over the course of the 12 weeks.

The investigators reported a significant improvement in IPSS, from 21.9 at baseline to 12.6 at 4 years.

“Initiating oral TU therapy with Kyzatrex at 400 mg BID is safe and effective in achieving therapeutic serum testosterone levels," wrote the authors.

Overall, 4 of 5 patients with low-grade disease who received bel-sar with light activation achieved a complete clinical response.

The investigators found that only 2 (1.4%) urology programs and 12 (5.3%) OB/GYN programs included female sexual dysfunction content.

“In the absence of infection, [drain and retain] is a safe strategy without further complications compared to the primary groups," said Thairo Pereira, MD.

“Before and after implant, we noted a statistically significant increase in both the length and the girth,” said Peter J. Arnold, MD.

At 5 years, 95.8% of patients in the SBRT arm were free from biochemical or clinical failure compared with 94.6% of patients in the control radiotherapy arm.

Data from the EMPIRE-2 trial also showed that 18F-fluciclovine resulted in significantly more boosts to the prostate bed.

The target action date for the application is June 13, 2025.

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

Overall, 15/16 patients had a true positive scan based on confirmatory imaging and/or biopsy, equating to a PPV of 93.75%.

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”

The application is supported by data from the pivotal phase 3 ARANOTE trial.

Patient recruitment for the phase 3 AMPLIFY trial is set to begin early next year.

Both 177Lu-PSMA-I&T and 64Cu-PSMA-I&T are currently in phase 3 development for use in prostate cancer diagnostics and treatment.

"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.